NO120686B - - Google Patents

Download PDF

Info

Publication number
NO120686B
NO120686B NO170180A NO17018067A NO120686B NO 120686 B NO120686 B NO 120686B NO 170180 A NO170180 A NO 170180A NO 17018067 A NO17018067 A NO 17018067A NO 120686 B NO120686 B NO 120686B
Authority
NO
Norway
Prior art keywords
ethanol
compound
ether
hydrogen
butylamino
Prior art date
Application number
NO170180A
Other languages
Norwegian (no)
Inventor
K Wetterlin
Original Assignee
Draco Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Draco Ab filed Critical Draco Ab
Priority to NO128170A priority Critical patent/NO124723B/no
Priority to NO302670A priority patent/NO132866C/no
Publication of NO120686B publication Critical patent/NO120686B/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/48Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation involving decarboxylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

Fremgangsmåte til fremstilling av den Method for producing it

bronchospasmolytisk virksomme forbindelse l-(3',5'-dihydroksyfenyl)-2-tert.butylaminoetanol. bronchospasmolytically active compound 1-(3',5'-dihydroxyphenyl)-2-tert.butylaminoethanol.

Foreliggende oppfinnel se vedrører fremstilling av en oralt virksom bronchospasmolytisk forbindelse, nemlig 1 -(3 ', 5 '-dihydroksyfenyl)-2-tert.bu-tylaminoetanol . The present invention relates to the production of an orally active bronchospasmolytic compound, namely 1-(3',5'-dihydroxyphenyl)-2-tert-butylaminoethanol.

Det er kjent et stort antall 1 - (3', 41-dihydroksyfenyl)-2-aminoetanoler A large number of 1-(3',41-dihydroxyphenyl)-2-aminoethanols are known

med bronchospasmolytisk aktivitet, men forbindelser av denne type med de to hydroksylgruppene i 3,4-stilling i benzen-ringen angripes i organismen av vis- with bronchospasmolytic activity, but compounds of this type with the two hydroxyl groups in the 3,4 position in the benzene ring are attacked in the organism by vis-

se enzymer, dvs. katekol-O-metyl-transferanse, COMT, som blant annet fin- see enzymes, i.e. catechol-O-methyl-transferase, COMT, which, among other things, fin-

nes i leveren. Ved et slikt angrep inaktiveres forbindelsene, og forbindelser av denne type har derfor relativt kortvarig virkning. Forbindelser med de to hydroksylgruppene i 3,5-stilling i benzen-ringen angripes imidlertid ikke av COMT. Det er kjent temmelig få forbindelser av denne sistnevnte type. Disse kan sammenfattes i den generelle formel: nes in the liver. In such an attack, the compounds are inactivated, and compounds of this type therefore have a relatively short-term effect. However, compounds with the two hydroxyl groups in the 3,5 position in the benzene ring are not attacked by COMT. Quite a few compounds of this latter type are known. These can be summarized in the general formula:

12 En forbindelse med formel I hvor R er hydrogen og R er en metylgruppe, er beskrevet i tysk patent nr. 865 315. Forbindelser med formel I, hvor R^ er hydrogen og R<2>er en 2-heksyl, 2-heptyl, 2-oktyl eller n-butylgruppe, er beskrevet i belgisk patent nr. 635 889, og forbindelser hvor R* er hydrogen og R er gruppen 12 A compound of formula I where R is hydrogen and R is a methyl group is described in German Patent No. 865 315. Compounds of formula I where R^ is hydrogen and R<2> is a 2-hexyl, 2-heptyl , 2-octyl or n-butyl group, is described in Belgian Patent No. 635,889, and compounds where R* is hydrogen and R is the group

hvor R 3er hydrogen eller en metylgruppe, er beskrevet i irsk patent nr. 1167/63, mens forbindelser hvor R 1 er hydrogen eller en metylgruppe og R<2> where R 3 is hydrogen or a methyl group, is described in Irish patent no. 1167/63, while compounds where R 1 is hydrogen or a methyl group and R<2>

er en isopropylgruppe er beskrevet i norsk patent nr. 108914. Disse kjente. forbindelser med formel I er bronchospasmolytisk aktive forbindelser med relativt langvarig virkning, men de er funnet å forårsake en økning av hjertefrekvensen og denne virkning reduserer forbindelsenes terapeutiske anvendelse. is an isopropyl group is described in Norwegian patent no. 108914. These known. compounds of formula I are bronchospasmolytically active compounds with a relatively long-lasting effect, but they have been found to cause an increase in heart rate and this effect reduces the therapeutic use of the compounds.

Ifølge oppfinnelsen tilveiebringes den nye forbindelse 1-(3<1>, 5'-dihydroksy-fenyl)-2-tert.butylaminoetanol som har langvarig virkning og som over-raskende nok bare forårsaker en meget svak virkning på hjertefrekvensen. According to the invention, the new compound 1-(3<1>, 5'-dihydroxy-phenyl)-2-tert.butylaminoethanol is provided which has a long-lasting effect and which, surprisingly, only causes a very weak effect on the heart rate.

Disse fordeler oppnåes ifølge oppfinnelsen ved å fremstille forbindelsen med formel II These advantages are achieved according to the invention by preparing the compound of formula II

og fysiologisk akseptable syreaddisjonssalter derav ved hjelp av i og for. Beg kjente metoder, nemlig: A. omsetning av en dikarbonylforbindelse med formel III med tert. -butylamin med formel IV under samtidig reduksjon ifølge følgende reaksjons - skjema: and physiologically acceptable acid addition salts thereof by means of i and for. Beg known methods, namely: A. reaction of a dicarbonyl compound of formula III with tert. -butylamine with formula IV during simultaneous reduction according to the following reaction scheme:

hvoretter R 3 ', om nødvendig, erstattes med hydrogen, eller omsetning B. av et epoksyd av formel VI med en forbindelse av formel VII ifølge følg- 3 4 hvoretter R og R , om nødvendig, erstattes med hydrogen, eller reduk-C. sjon av en forbindelse med formel IX ifølge følgende reaksjons skjema: after which R 3 ', if necessary, is replaced by hydrogen, or reaction B. of an epoxide of formula VI with a compound of formula VII according to following- 3 4 after which R and R , if necessary, are replaced by hydrogen, or reduc-C. tion of a compound of formula IX according to the following reaction scheme:

hvoretter R 3 og R 4, om nødvendig, erstattes med hydrogen, i hvilke formler R<3>er hydrogen eller en alkyl- eller alkanoylgruppe med høyst 5 karbonatomer eller en mono- eller bicyklisk aralkylgruppe med høyst 11 karbonatomer, slik som benzyl eller naftylmetyl, og R 4 er hydrogen eller en mono-eller bicyklisk aralkylgruppe med høyst 11 karbonatomer, after which R 3 and R 4 are, if necessary, replaced by hydrogen, in which formulas R<3> is hydrogen or an alkyl or alkanoyl group of up to 5 carbon atoms or a mono- or bicyclic aralkyl group of up to 11 carbon atoms, such as benzyl or naphthylmethyl , and R 4 is hydrogen or a mono- or bicyclic aralkyl group with no more than 11 carbon atoms,

hvoretter den erholdte forbindelse om ønsket omdannes til fysiologisk tålbare syreaddisjonssalter, og/eller oppdeles i sine optisk aktive former enten før after which the obtained compound is, if desired, converted into physiologically tolerable acid addition salts, and/or broken down into its optically active forms either before

3 , 4 3, 4

eller etter avspaltningen av beskyttelsesgruppene R og/eller R . or after the removal of the protecting groups R and/or R .

Det er innlysende at forbindelsen med formel II kan eksistere i form av optisk aktive isomere, som kan isoleres på en hvilken som helst i prinsippet kjent metode for spalting av et amin, og det er underforstått at en slik metode omfattes av foreliggende oppfinnelse. It is obvious that the compound of formula II can exist in the form of optically active isomers, which can be isolated by any method known in principle for cleaving an amine, and it is understood that such a method is covered by the present invention.

Den foretrukne fremgangsmåte til fremstilling av forbindelsen med formel II er den ovenfor angitte metode C. Utgangsmaterialet med formel IX kan oppnåes på en hvilken som helst ønsket måte, f. eks. ved følgende reaksjonsskjema. The preferred method for the preparation of the compound of formula II is the above-mentioned method C. The starting material of formula IX can be obtained in any desired way, e.g. by the following reaction scheme.

som kan modifiseres på forskjellige i og for seg kjente måter, som f. eks. ved at det tredje og andre trinnet fra slutten av skjemaet kan erstattes med: which can be modified in various ways known per se, such as e.g. in that the third and second steps from the end of the form can be replaced with:

hvorved bromeringen kan utføres ved anvendelse av brom ved lav temperatur eller ved hjelp av kobber (II) bromid. whereby the bromination can be carried out using bromine at low temperature or with the help of copper (II) bromide.

Reduksjonen av forbindelsen med formel IX kan utføres f. eks. The reduction of the compound of formula IX can be carried out e.g.

a) ved katalytisk reduksjon, f. eks. med Raney-nikkel eller med palladiumkull, eller platinaoksyd eller b) kjemisk reduksjon, f. eks. med litiumaluminiumhydrid eller natriumborhydrid i hvilket tilfelle R 3er en hydroksy-beskyttelsesgruppe, eller c) kjemisk reduksjon av karbonylgruppen, f. eks. med litiumaluminiumhydrid eller natriumborhydrid, hvoretter hydroksy-beskyttelsesgruppene a) by catalytic reduction, e.g. with Raney nickel or with palladium charcoal, or platinum oxide or b) chemical reduction, e.g. with lithium aluminum hydride or sodium borohydride in which case R 3 is a hydroxy protecting group, or c) chemical reduction of the carbonyl group, e.g. with lithium aluminum hydride or sodium borohydride, after which the hydroxy protecting groups

R^ og R fjernes ved katalytisk reduksjon, f. eks. med palladiumkull eller platinaoksyd. R^ and R are removed by catalytic reduction, e.g. with palladium charcoal or platinum oxide.

Hvis R 3 i formel VIII er en alkylgruppe, kan den erstattes med hydrogen ved hjelp av eter spaltende midler, f. eks. ved å benytte bortribromid ved lav temperatur eller ved å oppvarme med hydrogen-halogenider. I dette tilfelle be-skyttes den alkoholiske hydroksylgruppen fortrinnsvis ved acetylering og spalt-ingen utføres under anvendelse av hydrobromsyre i vannfri iseddik eller iaeddik/ eddiksyre-anhydrid og blir deretter hydrolysert. Hvis R<3>i formel VIII er en acylrest, kan denne avspaltes ved behandling med syrer. Hvis R<4>i formel VIII er en aralkylgruppe, kan denne fjernes ved hydrogenolyse. If R 3 in formula VIII is an alkyl group, it can be replaced by hydrogen using ether-cleaving agents, e.g. by using boron tribromide at low temperature or by heating with hydrogen halides. In this case, the alcoholic hydroxyl group is preferably protected by acetylation and the cleavage is carried out using hydrobromic acid in anhydrous glacial acetic acid or acetic acid/acetic anhydride and is then hydrolysed. If R<3> in formula VIII is an acyl residue, this can be cleaved by treatment with acids. If R<4> in formula VIII is an aralkyl group, this can be removed by hydrogenolysis.

Den nye forbindelsen 1-(3 \ 5'-dihydroksyfenyl)-2-(t-butylamino)-etanol er en meget god bronkodilator og den har bare meget svak kardioakselererende effekt. Således har forbindelsen både in vitro og in vivo vist seg å være en mer virksom bronkodilator enn 1-(3 1, 51 -dihydroksyfenyl)-2-(isopropylamino)-etanol og effektens varighet er lengre enn for den kjente forbindelse og ved forsøk-på isolert kaninhjerte er den kardioakselererende effekt bare l/l5 av den til isopro-pylaminoforbindelsen. Forholdet mellom den hjertestimulerende effekt og bron-kodilatoreffekten er også demonstrert på spontant slående aurikelpreparat og spiralskåret trakeapreparat fra marsvin, når begge forbindelsene var plasert i samme bad. Når forbindelsen fremstilt ifølge oppfinnelsen langsomt ble innført i badoppløsningen, ble det oppnådd en bronkodilatering uten noen virkning på hjer-temuskelpreparatet. Den svake kardioakselererende effekt for den fremstilte t-butylaminoforbindelsen er også blitt verifisert ved sirkulasjons studier av forbindelsen i en bedøvet katt. The new compound 1-(3\5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol is a very good bronchodilator and it has only a very weak cardioaccelerating effect. Thus, the compound both in vitro and in vivo has been shown to be a more effective bronchodilator than 1-(3 1,51 -dihydroxyphenyl)-2-(isopropylamino)-ethanol and the duration of the effect is longer than for the known compound and in experimental on isolated rabbit heart the cardioaccelerating effect is only 1/15 of that of the isopropylamino compound. The relationship between the heart stimulating effect and the bronchodilator effect has also been demonstrated on a spontaneously beating auricle preparation and a spirally cut trachea preparation from a guinea pig, when both compounds were placed in the same bath. When the compound produced according to the invention was slowly introduced into the bath solution, bronchodilation was achieved without any effect on the heart muscle preparation. The weak cardioaccelerating effect of the prepared t-butylamino compound has also been verified by circulation studies of the compound in an anesthetized cat.

Svekkingen av den kardioakselererende effekt oppnåes således ved å erstatte et sekundært karbonatom med et tertiært. The weakening of the cardioaccelerating effect is thus achieved by replacing a secondary carbon atom with a tertiary one.

r Den nye forbindelse kan administreres i form av salter med fysiologisk akseptable syrer. Egnede syrer som kan anvendes er f. eks. saltsyre, hydrobromsyre, svovelsyre, fumarsyre, sitronsyre, vinsyre, maleinsyre eller ravsyre. r The new compound can be administered in the form of salts with physiologically acceptable acids. Suitable acids that can be used are e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, fumaric acid, citric acid, tartaric acid, maleic acid or succinic acid.

Det kan tilberedes farmasøytiske preparater inneholdende som aktiv bestanddel den ifølge oppfinnelsen fremstilte forbindelse sammen med en far-masøytisk bærer. Slike preparater kan utformes for oral, bronkial, rektal eller parenteral administrasjon, Pharmaceutical preparations can be prepared containing as active ingredient the compound produced according to the invention together with a pharmaceutical carrier. Such preparations can be designed for oral, bronchial, rectal or parenteral administration,

Følgende eksempler illustrerer oppfinnelsen. The following examples illustrate the invention.

Eksempel 1 - Fremstilling av 3 , 5 -dibenzyloksy-c*-(t-butylamino)-acetofenon Example 1 - Preparation of 3,5-dibenzyloxy-c*-(t-butylamino)-acetophenone

benyttet som utgangsmateriale. used as starting material.

a) Etyl- 3 , 5 - dihydroksybenzoat a) Ethyl-3,5-dihydroxybenzoate

308 g fc-resorcylsyre ble oppløst i 1000 ml absolutt etanol og 25 ml 308 g of fc-resorcylic acid were dissolved in 1000 ml of absolute ethanol and 25 ml

konsentrert svovelsyre, ble tilsatt. Reaksjonsblandingen ble kokt under til - bakeløp i 20 timer. Etanolen ble avdampet og resten heilt i vann og ekstrahert med eter. Eterfasen ble vasket med natriumbikarbonatoppløsning og vann og tørket med magnesiumsulfat. Etter avdamping av eteren ble en krystallinsk rest oppnådd. Esteren ble omkrystallisert fra vann: smeltepunkt 128° - 130°. concentrated sulfuric acid, was added. The reaction mixture was refluxed for 20 hours. The ethanol was evaporated and the residue poured into water and extracted with ether. The ether phase was washed with sodium bicarbonate solution and water and dried with magnesium sulfate. After evaporation of the ether, a crystalline residue was obtained. The ester was recrystallized from water: mp 128°-130°.

b) 3 , 5- dibenzyloksybenzQByre b) 3, 5-dibenzyloxybenzQByre

I en 2-liters trehalskolbe forsynt med en rører og en tilbakeløpskjøler, In a 2-liter three-necked flask fitted with a stirrer and a reflux condenser,

ble 221 g etyl-3, 5-dihydroksybenzoat, 750 ml absolutt etanol, 360 ml benzylklorid og 210 g kaliumkarbonat innført. Reaksjonsblandingen ble kokt under tilbake-løp, omrørt i 20 timer og filtrert i varm tilstand. Etanolen ble inndampet og til resten ble vann og natriumhydroksyd tilsatt til alkalisk reaksjon. Vannfasen ble ekstrahert med eter og tørket med magnesiumsulfat. Eteren ble avdampet og resten av benzylklorid avdestillert under redusert trykk, Den resterende olje ble tilbakeløpskokt i 3 timer på et vannbad med 150 g natriumhydroksyd i 750 ml etanbl og 50 ml vann. Etanolen ble avdampet og 250 ml vann tilsatt. Ved sur-gjøring av oppløsningen med 5 N saltsyre utkrystalliserte syren seg. Omkrystallisering fra etylacetat: sme ltepunkt 214 - 216UC. 221 g of ethyl 3,5-dihydroxybenzoate, 750 ml of absolute ethanol, 360 ml of benzyl chloride and 210 g of potassium carbonate were introduced. The reaction mixture was refluxed, stirred for 20 hours and filtered while hot. The ethanol was evaporated and to the residue water and sodium hydroxide were added for an alkaline reaction. The aqueous phase was extracted with ether and dried with magnesium sulfate. The ether was evaporated and the remainder of benzyl chloride distilled off under reduced pressure. The remaining oil was refluxed for 3 hours on a water bath with 150 g of sodium hydroxide in 750 ml of ethanol and 50 ml of water. The ethanol was evaporated and 250 ml of water was added. When the solution was acidified with 5 N hydrochloric acid, the acid crystallized. Recrystallization from ethyl acetate: melting point 214 - 216UC.

c) i 3 , 5- dibenzyloksybenz oylklorid c) in 3,5-dibenzyloxybenzoyl chloride

167 g dibenzyloksybenzosyre og 400 ml nylig destillert tionylklorid, ble 167 g of dibenzyloxybenzoic acid and 400 ml of freshly distilled thionyl chloride were

tilbakeløpskokt på et oljebad i en time. Overskudd tionylklorid ble avdestillert ved redusert trykk og en krystallinsk masse var tilbake. Omkrystallis er ing fra petroleter (kokepunkt 60° - 85°C), smeltepunkt 73° - 74°C. refluxed in an oil bath for one hour. Excess thionyl chloride was distilled off under reduced pressure and a crystalline mass remained. Recrystallized from petroleum ether (boiling point 60° - 85°C), melting point 73° - 74°C.

d) ^ 3 , 5- dibenzyloksydiazoacetofenon d) ^ 3 , 5- dibenzyloxydiazoacetophenone

Diazometan ble fremstilt ifølge kjente metoder. 86 g N-nitroso-p-toluen-sulfometylamid i eter ble langsomt tilsatt til en oppløsning av 24 g kalium- hfydroksyd i 40 ml vann og 100 ml dietylenglykolmonoetyleter i 40 ml eter. Reaksjonskolben ble oppvarmet til 55°-65°C på et vannbad og dannet diazometan ble avdestillert til en mottagerkolbe inneholdende 71 g 3,5-dibenzyloksybenzoylklorid i 250 ml absolutt eter ved -25°C. Reaksjonsblandingen fikk langsomt anledning til å nå romtemperatur. Eter oppløsningen ble benyttet direkte i neste reaksjon. Diazomethane was prepared according to known methods. 86 g of N-nitroso-p-toluene-sulfomethylamide in ether was slowly added to a solution of 24 g of potassium hydroxide in 40 ml of water and 100 ml of diethylene glycol monoethyl ether in 40 ml of ether. The reaction flask was heated to 55°-65°C on a water bath and the diazomethane formed was distilled off into a receiving flask containing 71 g of 3,5-dibenzyloxybenzoyl chloride in 250 ml of absolute ether at -25°C. The reaction mixture was slowly allowed to reach room temperature. The ether solution was used directly in the next reaction.

e) 3 , 5- dibenzyloksy- cu- bromacetofenon e) 3, 5-dibenzyloxy-cubromacetophenone

Til eteroppløsningen fra foregående reaksjon ble 300 ml benzen og To the ether solution from the previous reaction was added 300 ml of benzene and

eter mettet med hydrogenbromid tilsatt til utviklingen av nitrogen opphørte. Etter at oppløsningen var inndampet, ble en krystallinsk rest oppnådd. Krystallene var oppløselige i xylen og kunne utfelles med petroleumeter (kokepunkt 40° - 60°C) og ble vasket med absolutt eter, smeltepunkt 82°-84°C. ether saturated with hydrogen bromide added until the evolution of nitrogen ceased. After the solution was evaporated, a crystalline residue was obtained. The crystals were soluble in xylene and could be precipitated with petroleum ether (boiling point 40°-60°C) and were washed with absolute ether, melting point 82°-84°C.

På lignende måte ble 3 , 5-dibenzyloksy-««»-kloracetofenon fremstilt. Smeltepunkt 78° - 80°C. In a similar manner, 3,5-dibenzyloxy-""-chloroacetophenone was prepared. Melting point 78° - 80°C.

f) 3 , 5 - dibenzyloksy- u>-( t- butylamino) - acetofenon f) 3,5-dibenzyloxy-u>-(t-butylamino)-acetophenone

I. 5 g t-butylamin og 85 ml absolutt etanol ble plasert i en 250 ml's I. 5 g of t-butylamine and 85 ml of absolute ethanol were placed in a 250 ml

kolbe forsynt med en tilbakeløpskjøler, og blandingen ble oppvarmet til til - bakeløpskoking. Reaksjonen ble utført under nitrogen. "Ved tilbakeløpstem-peraturen ble 4.1 g 3, 5-dibenzyloksy-bromacetofenon i 15 ml benzen tilsatt. Blandingen ble tilbakeløpskokt i 20 timer og etter inndamping ble en gul olje oppnådd. Denne olje ble rystet med absolutt eter og dette gå hvite krystal- flask fitted with a reflux condenser, and the mixture was heated to reflux. The reaction was carried out under nitrogen. "At the reflux temperature, 4.1 g of 3,5-dibenzyloxy-bromoacetophenone in 15 ml of benzene was added. The mixture was refluxed for 20 hours and after evaporation a yellow oil was obtained. This oil was shaken with absolute ether and this left white crystals

ler (t-butylaminhydrobromid) . Krystallene ble frafiltrert og vasket med eter. Til de forenede eterfasene ble 10% hydrobromsyre tilsatt, og dette ga et hvitt bunnfall. Dette bunnfall ble frafiltrert og vasket grundig med vann og eter. Om - krystallisering fra etanol ga et produkt med et smeltepunkt på 196° - 198°C. clay (t-butylamine hydrobromide) . The crystals were filtered off and washed with ether. To the combined ether phases 10% hydrobromic acid was added, and this gave a white precipitate. This precipitate was filtered off and washed thoroughly with water and ether. Re-crystallization from ethanol gave a product with a melting point of 196°-198°C.

Trinnene d) og e) kan erstattes med følgende to trinn: Steps d) and e) can be replaced by the following two steps:

j|) 3 , 5- dibenzyloksy- acetofenon j|) 3 , 5-dibenzyloxy-acetophenone

70 g 3, 5-dibenzyloksybenzoylklorid i tørr benzen ble langsomt tilsatt 70 g of 3,5-dibenzyloxybenzoyl chloride in dry benzene was slowly added

til en oppløsning av dietyletoksymagnesiummalonat fremstilt på kjent måte. Reaksjonsblandingen ble tilbakeløpskokt natten over, og etter avkjøling ble 300 ml benzen og 200 ml 5 N svovelsyre tilsatt for å hydrolysere blandingen. Benzenfasen ble vasket tre ganger med vann og tørket med magnesiumsulfat. Benzenen ble inndampet og overskudd dietylmalonat avdestillert under redusert trykk. Til resten ble 400 ml dioksan, 80 ml vann og 40 ml konsentrert saltsyre tilsatt.Reaksjonsblandingen ble oppvarmet i 24 timer på et oljebad ved 130°C. Etter inndamping ble en brun olje oppnådd og denne krystalliserte seg etter henstand. Omkrystallisering fra etanol: smeltepunkt 60°-6l°C. to a solution of diethylethoxymagnesium malonate prepared in a known manner. The reaction mixture was refluxed overnight, and after cooling, 300 mL of benzene and 200 mL of 5 N sulfuric acid were added to hydrolyze the mixture. The benzene phase was washed three times with water and dried with magnesium sulfate. The benzene was evaporated and excess diethyl malonate distilled off under reduced pressure. To the residue, 400 ml of dioxane, 80 ml of water and 40 ml of concentrated hydrochloric acid were added. The reaction mixture was heated for 24 hours in an oil bath at 130°C. After evaporation, a brown oil was obtained and this crystallized after standing. Recrystallization from ethanol: melting point 60°-61°C.

h) 3 , 5- dibenzyloksy- u>- bromacetofenon h) 3,5-dibenzyloxy-u>-bromoacetophenone

II. 2 g kobber (II) bromid ble anbragt i en trehalskolbe forsynt med en II. 2 g of copper (II) bromide were placed in a three-necked flask fitted with a

rører og tilbakeløpskjøler. 25 ml etylacetat ble tilsatt og blandingen oppvarmet til tilbakeløpskoking under omrøring. 10 g 3, 5-dibenzyloksyacetofenon i 30 ml stirrer and reflux cooler. 25 ml of ethyl acetate was added and the mixture heated to reflux with stirring. 10 g of 3, 5-dibenzyloxyacetophenone in 30 ml

Varm kloroform ble tilsatt og tilbakeløpskokingen ble fortsatt til den svart-grønne fargen ble forandret til lys brun. Det dannede kobber (I) bromid ble frafiltrert og etter inndamping av filtratet ble en brun olje oppnådd som snart krystalliserte seg. Omkrystallisering fra etanol: smeltepunkt 82°-84°C. Hot chloroform was added and reflux was continued until the black-green color changed to light brown. The formed copper (I) bromide was filtered off and after evaporation of the filtrate a brown oil was obtained which soon crystallized. Recrystallization from ethanol: melting point 82°-84°C.

Dette trinn h) kan alternativt erstattes med i). This step h) can alternatively be replaced by i).

i) 3 , 5- dibenzyloksy- 6»- bromacetofenon i) 3,5-dibenzyloxy-6"-bromoacetophenone

I en 250 ml's trehalskolbe forsynt med en rører og en tilbakeløps-kjøler og en dråpetrakt, ble 5. 0 g 3 , 5-dibenzyloksyacetofenon i 90 ml kloroform innført. Etter dette ble 15 dråper iseddik mettet ved 0°C med hydrogenbromid tilsatt til oppløsningen. 4 ml av en oppløsning fremstilt av 2.4 g brom og 25 ml kloroform ble tilsatt. Reaksjonsblandingen ble oppvarmet til tilbake-løpskoking og deretter avkjølt hurtig til 0°C. Den gjenværende bromoppløsning ble langsomt tilsatt under omrøring og avkjøling og deretter omrørt ytterligere 1 time ved romtemperatur og sluttlig oppvarmet i en halv time ved tilbakeløps-temperatur. Etter avkjøling til romtemperatur ble nitrogengass innført for å fjerne resterende hydrogenbromid. Petroleumeter (kokepunkt 60°-85°C) ble tilsatt og reaksjonsblandingen vasket med kald natriumbikarbonatoppløsning og vann mettet med natriumklorid. Den organiske fasen ble tørket med magnesiumsulfat Og inndampet. Den resterende olje krystalliserte seg etter henstand. Om-t, krystallisering fra etanol ga et smeltepunkt på 82° - 84°C. Into a 250 ml three-necked flask fitted with a stirrer and a reflux condenser and a dropping funnel, 5.0 g of 3,5-dibenzyloxyacetophenone in 90 ml of chloroform was introduced. After this, 15 drops of glacial acetic acid saturated at 0°C with hydrogen bromide were added to the solution. 4 ml of a solution prepared from 2.4 g of bromine and 25 ml of chloroform was added. The reaction mixture was heated to reflux and then cooled rapidly to 0°C. The remaining bromine solution was slowly added with stirring and cooling and then stirred for a further 1 hour at room temperature and finally heated for half an hour at reflux temperature. After cooling to room temperature, nitrogen gas was introduced to remove residual hydrogen bromide. Petroleum ether (boiling point 60°-85°C) was added and the reaction mixture was washed with cold sodium bicarbonate solution and water saturated with sodium chloride. The organic phase was dried with magnesium sulfate and evaporated. The remaining oil crystallized after standing. About-t, crystallization from ethanol gave a melting point of 82° - 84°C.

Trinnene d) og e) ovenfor kan erstattes med følgende to trinn: Steps d) and e) above can be replaced by the following two steps:

j) 3 , 5- dibenzyloksy- acetofenon j) 3,5-dibenzyloxy-acetophenone

5.0 g 50 % natriumhydridsuspensjon og et par ml benzen ble tilsatt en 500 ml trehalskolbe utstyrt med en rører, kjøler samt en dråpetrakt. 18.1 g etyl 3,5-dibenzyloksybenzoat i 150 ml tørr benzen ble så tilsatt. Reaksjonsblandingen ble rørt og oppvarmet på et oljebad (90°-100°C), hvoretter 4,5 g etylacetat i 25 ml tørr benzen langsomt ble tilsatt hvoretter oppvarmingen og røringen ble fortsatt i 7 timer. Reaksjonsblandingen ble avkjølt, et par ml etanol ble tilsatt hvoretter hele blandingen ble helt over i 150 ml 50% eddiksyre-oppløsmng. Den sure vannfasen ble ekstrahert med eter, og eterfasen ble vasr. ket med vann, natriumbikarbonatoppløsning og vann og så tørket med magnesiumsulfat. Etter fordampning'av oppløsningsmidlene fikk man en olje, som så ble behandlet med 80 ml dioksan, 16 ml vann og 8 ml konsentrert saltsyre, hvoretter blandingen ble oppvarmet på et oljebad ved 130° - 140°C i 15 timer. Etter fordampning av oppløsningsmidlene ble eter tilsatt, og eterfasen ble vasket med vann, 2 N natriumhydroksydoppløsning og vann. Eterfasen ble så fordampet, og residuet ble oppløst i varm etanol hvoretter man tilsatte 200 ml av en 1 N natriumhydroksydoppløsning. Blandingen ble tilbakeløpskokt i 5 timer for å hyjlrolysere det gjenværende etyl 3 , 5-dibenzyloksyberizoat. Etanolen ble for- 5.0 g of 50% sodium hydride suspension and a couple of ml of benzene were added to a 500 ml three-necked flask equipped with a stirrer, condenser and a dropping funnel. 18.1 g of ethyl 3,5-dibenzyloxybenzoate in 150 ml of dry benzene was then added. The reaction mixture was stirred and heated in an oil bath (90°-100°C), after which 4.5 g of ethyl acetate in 25 ml of dry benzene was slowly added, after which the heating and stirring were continued for 7 hours. The reaction mixture was cooled, a few ml of ethanol were added, after which the entire mixture was poured into 150 ml of 50% acetic acid solution. The acidic aqueous phase was extracted with ether, and the ether phase became aqueous. keted with water, sodium bicarbonate solution and water and then dried with magnesium sulfate. After evaporation of the solvents, an oil was obtained, which was then treated with 80 ml of dioxane, 16 ml of water and 8 ml of concentrated hydrochloric acid, after which the mixture was heated in an oil bath at 130°-140°C for 15 hours. After evaporation of the solvents, ether was added and the ether phase was washed with water, 2N sodium hydroxide solution and water. The ether phase was then evaporated, and the residue was dissolved in hot ethanol, after which 200 ml of a 1 N sodium hydroxide solution was added. The mixture was refluxed for 5 hours to hydrolyze the remaining ethyl 3,5-dibenzyloxyberisoate. The ethanol was pre-

dampet, hvoretter vannfasen ble ekstrahert med eter, og de samlede eter-faser ble vasket med vann, tørket med magnesiumsulfat og fordampet for opp-løsningsmidler. Den gjenværende olje krystalliserte fra petroleter (kokepunkt 80° - 1I0°C), smeltepunkt 61.5° - 62.0°C. evaporated, after which the aqueous phase was extracted with ether, and the combined ether phases were washed with water, dried with magnesium sulfate and evaporated for solvents. The remaining oil crystallized from petroleum ether (boiling point 80° - 110°C), melting point 61.5° - 62.0°C.

k) 3 , 5- dibenzyloksy-& »- bromacetonfenon k) 3,5-dibenzyloxy-&»-bromoacetonephenone

20.0 g 3,5-dibenzyloksyacetofenon ble oppløst i 460 ml tørr eter og avkjølt til 0°C. 9,7 g brom oppløst i 30 ml tørr, etanolfri kloroform ble deretter langsomt tilsatt. Under denne tilsetning ble temperaturen holdt på 0°C. Temperaturen i reaksjonsblandingen ble så langsomt hevet til romtemperatur 20.0 g of 3,5-dibenzyloxyacetophenone was dissolved in 460 ml of dry ether and cooled to 0°C. 9.7 g of bromine dissolved in 30 ml of dry, ethanol-free chloroform was then slowly added. During this addition, the temperature was kept at 0°C. The temperature of the reaction mixture was then slowly raised to room temperature

og ble holdt på denne temperatur i 2. 5 timer under røring. Eteren ble så fordampet ved romtemperatur, og den gjenværende olje utkrystalliserte ved henstand. Produktet er identisk med de man fikk under eksempel 1 i). and was kept at this temperature for 2.5 hours with stirring. The ether was then evaporated at room temperature, and the remaining oil crystallized on standing. The product is identical to those obtained under example 1 i).

Eksempel 2. - Fremstilling av 1-(3', 5'-dihydroksyfenyl) -2-(t-butylamino) - Example 2. - Preparation of 1-(3', 5'-dihydroxyphenyl)-2-(t-butylamino)-

etanol og dets salter. ethanol and its salts.

a) En oppløsning av 6.8 g av hydratet av 1-glyoksyloyl-3 , 5-dibenzylok-sybenzen i 50 ml metanol ble tilsatt 7.0 g t-butylamin og 30 ml benzen. Reaksjonsblandingen ble kokt under tilbakeløp i 3 timer hvoretter oppløsnings mid-lene ble fordampet. Den gjenværende olje krystalliserte når etanol ble tilsatt. Smeltepunkt 78. 5°- 79. 5°C. 2. 5 g av denne forbindelse i 75 ml absolutt etanol ble hydrogenert under normale betingelser med Raney-nikkel. Etter frafilt - rering av katalysatoren og fordampning av oppløsningsmidlene, ble den gjen-vætende olje tørket med etanol/benzen. Basen ble i etanol behandlet med hydrogenbromid i etanol, hvoretter oppløsningsmidlene ble fordampet. Residuet kan utkrystalliseres fra iseddik/kloroform. a) A solution of 6.8 g of the hydrate of 1-glyoxyloyl-3,5-dibenzyloxybenzene in 50 ml of methanol was added to 7.0 g of t-butylamine and 30 ml of benzene. The reaction mixture was refluxed for 3 hours, after which the solvents were evaporated. The remaining oil crystallized when ethanol was added. Melting point 78.5°- 79.5°C. 2. 5 g of this compound in 75 ml of absolute ethanol was hydrogenated under normal conditions with Raney nickel. After filtering off the catalyst and evaporating the solvents, the rewetting oil was dried with ethanol/benzene. The base in ethanol was treated with hydrogen bromide in ethanol, after which the solvents were evaporated. The residue can be crystallized from glacial acetic acid/chloroform.

IR-spektrumet av dette produkt er identisk med det man får av produktet i avsnitt 2 c). The IR spectrum of this product is identical to that obtained from the product in section 2 c).

b) En oppløsning av 3.5 g 3 ', 5'-dibenzyloksyfenyl-enoksyetan i 100 ml etanol ble tilsatt 2.5 g t-butylamin i 20 ml etanol. Reaksjonsblandingen ble til-bakeløpskokt i 4 timer hvoretter oppløsningsmidlene ble fordampet. Det krystallinske residum kan omkrystalliseres fra absolutt eter. Smeltepunktet av 1 - b) A solution of 3.5 g of 3', 5'-dibenzyloxyphenyl-enoxyethane in 100 ml of ethanol was added to 2.5 g of t-butylamine in 20 ml of ethanol. The reaction mixture was refluxed for 4 hours after which the solvents were evaporated. The crystalline residue can be recrystallized from absolute ether. The melting point of 1 -

(3 ', 5'-dibenzyloksyfenyl)-2-(t-butylamino)-etanol er 119°- I22°C. Fremstillingen av saltet og reduksjonen kan utføres på samme måte som beskrevet under avsnitt 2 a). (3', 5'-dibenzyloxyphenyl)-2-(t-butylamino)-ethanol is 119°-122°C. The preparation of the salt and the reduction can be carried out in the same way as described under section 2 a).

c) 2.4 g 3 , 5-dibenzyloksy-6»-(t-butylamino)-acetofenonhydrobromid i 200 ml iseddik ble hydrogenert i nærvær av 0.3 g 10% palladium/trekull ved romtemperatur og normalt trykk. Etanol ble tilsatt for å oppløse det utfelte reak-sjonsprodukt. Katalysatoren ble frafiltrert, residuet fordampet til tørrhet hvoretter 50 ml absolutt etanol ble tilsatt og oppløsningen hydrogenert i nærvær av 6.3 g 10 7" palladium trekull ved 35°C og 5 atm. trykk. Katalysatoren ble frafiltrert, hvoretter residuet ble fordampet til tørrhet. Omkrystallisert fra iseddik/kloroform: smeltepunkt 93° - 97°C for monohydratet. Den ikke-hydratiserte forbindelse har et smeltepunkt på 205° - 206°C (dekomponering). c) 2.4 g of 3,5-dibenzyloxy-6"-(t-butylamino)-acetophenone hydrobromide in 200 ml of glacial acetic acid was hydrogenated in the presence of 0.3 g of 10% palladium/charcoal at room temperature and normal pressure. Ethanol was added to dissolve the precipitated reaction product. The catalyst was filtered off, the residue evaporated to dryness after which 50 ml of absolute ethanol was added and the solution hydrogenated in the presence of 6.3 g 10 7" palladium charcoal at 35°C and 5 atm. pressure. The catalyst was filtered off, after which the residue was evaporated to dryness. Recrystallized from glacial acetic acid/chloroform: mp 93° - 97°C for the monohydrate The non-hydrated compound has a melting point of 205° - 206°C (decomposition).

d) En oppløsning av 32 g benzyl-t-butylamin i 300 ml absolutt etanol ved tilbakeløpstemperatur ble tilsatt 32 g 3 , 5-dibenzyloksy-6>-bromacetofe- d) A solution of 32 g of benzyl-t-butylamine in 300 ml of absolute ethanol at reflux temperature was added to 32 g of 3,5-dibenzyloxy-6>-bromoacetophe-

non i 100 ml tørr benzen. Blandingen ble tilbakeløpskokt i 20 timer og deretter fordampet for oppløsningsmidler. Ved tilsetning av eter, fikk man ut- non in 100 ml of dry benzene. The mixture was refluxed for 20 hours and then evaporated for solvents. By adding ether, one obtained

felt benzyl-t-butylaminohydrobromid. Den utfelte forbindelse ble frafiltert, field benzyl-t-butylaminohydrobromide. The precipitated compound was filtered off,

og filtratet ble tilsatt et overskudd av 2N svovelsyre. Med denne tilsetning fikk man utfelt hydrogensulfatet av 3 , 5-dibenzyloksy-W-(benzyl-t-butylamin) - acetofenon. Omkrystallisert fra aceton/eter. Ettersom produktet krystal-liserer med forskjellige organiske oppløsningsmidler, så vil smeltepunktet variere med den type og den mengde oppløsningsmiddel som anvendes, men produktet kan brukes direkte for hydrogenering. 1 5 g 3 , 5-dibenzyloksy-<«»-(benzyl-t-butylamino) - acetofenon-hydrogen-sulfat i 200 ml iseddik ble hydrogenert i et Parr-trykkreaksjonsapparat i nærvær av 1.5 g 10% palladium/trekull ved 50°C og 5 atm. trykk. Reaksjonstiden var 5 timer. Katalysatoren ble frafiltrert, filtratet'fordampet til tørrhet hvoretter man fikk hydrogensulfatet av 1 -(3', 51-dihydroksyfenyl) -2-(t-butylamino) - etanol. Denne forbindelse er hygroskopisk, men kan overføres til det ikke-hyg-roskopiske sulfat på følgende måte. and an excess of 2N sulfuric acid was added to the filtrate. With this addition, the hydrogen sulfate of 3,5-dibenzyloxy-N-(benzyl-t-butylamine)-acetophenone was precipitated. Recrystallized from acetone/ether. As the product crystallizes with different organic solvents, the melting point will vary with the type and amount of solvent used, but the product can be used directly for hydrogenation. 15 g of 3,5-dibenzyloxy-<«»-(benzyl-t-butylamino)-acetophenone-hydrogen-sulphate in 200 ml of glacial acetic acid was hydrogenated in a Parr pressure reaction apparatus in the presence of 1.5 g of 10% palladium/charcoal at 50° C and 5 atm. Print. The reaction time was 5 hours. The catalyst was filtered off, the filtrate evaporated to dryness after which the hydrogen sulfate of 1-(3',51-dihydroxyphenyl)-2-(t-butylamino)-ethanol was obtained. This compound is hygroscopic, but can be transferred to the non-hygroscopic sulfate in the following way.

Hydrogensulfatet ble oppløst i vann, og oppløsningens pH ble justert The hydrogen sulphate was dissolved in water, and the pH of the solution was adjusted

til 5.6 (pH-meter) med en 0.1 N natriumhydroksydoppløsning. Vannoppløsningen ble fordampet til tørrhet, og residuet ble tørket med absolutt etanol/benzen og igjen fordampet til tørrhet. Den gjenværende krystallinske blanding ble ekstrahert i et Soxhlet ekstraksjonsapparat med absolutt metanol. Fra metanolfasen fikk man utkrystallisert sulfatet av 1-(3', 5'-dihydroksyfenyl)-2-(t-butylamino}-etanol. Smeltepunkt 246° - 248°C. to 5.6 (pH meter) with a 0.1 N sodium hydroxide solution. The water solution was evaporated to dryness, and the residue was dried with absolute ethanol/benzene and again evaporated to dryness. The remaining crystalline mixture was extracted in a Soxhlet extractor with absolute methanol. The sulfate of 1-(3', 5'-dihydroxyphenyl)-2-(t-butylamino}-ethanol was crystallized from the methanol phase. Melting point 246° - 248°C.

Sulfatet kan også fremstilles på følgende måte: Etter hydrogenering med palladium/trekull i iseddik, frafiltreres katalysatoren. Ved forhøyet temperatur tilsetter man den teoretiske mengde vannfri natriumacetat, og oppløs-ningen røres i 5 minutter under utfelling av natriumsulfat som så frafiltreres. The sulphate can also be prepared in the following way: After hydrogenation with palladium/charcoal in glacial acetic acid, the catalyst is filtered off. At an elevated temperature, the theoretical quantity of anhydrous sodium acetate is added, and the solution is stirred for 5 minutes during the precipitation of sodium sulphate, which is then filtered off.

I filtratet kan således sulfatet av 1-(3', 51-dihydroksyfenyl)-2-(t-butylamino) - etanol isoleres. In the filtrate, the sulfate of 1-(3',51-dihydroxyphenyl)-2-(t-butylamino)-ethanol can thus be isolated.

e) 6.3 g 3 , 5-diacetoksy-<«>-bromacetofenon oppløst i 100 ml tørr benzen ble tilsatt 7.0 g benzyl-t-butylamin i 50 ml tørr benzen. Blandingen ble tilbake-løpskokt i 3 timer og deretter fordampet for oppløsningsmidler. Ved tilsetning av absolutt eter får man utfelt benzyl-t-butylaminohydrobromid, som så ble frafiltrert. Eterfasen ble behandlet med hydrogenbromid i eter inntil oppløs-ningen var svakt sur. e) 6.3 g of 3,5-diacetoxy-<«>-bromoacetophenone dissolved in 100 ml of dry benzene was added to 7.0 g of benzyl-t-butylamine in 50 ml of dry benzene. The mixture was refluxed for 3 hours and then evaporated for solvents. When absolute ether is added, benzyl-t-butylaminohydrobromide is precipitated, which was then filtered off. The ether phase was treated with hydrogen bromide in ether until the solution was slightly acidic.

Den utfelte saltblanding ble behandlet med vann for å få oppløst benzyl-t-butylaminohydrobromid. Krystallene, ble filtrert, vasket med vann og omkrystallisert ved å oppløse dem i etanol og så foreta omkrystallisasjonen i absolutt eter. Hydrobromidet av (3 , 5-diacetoksy-6»-(benzyl-t -butylamino) - acetofenon har et smeltepunkt på 171°- 173°C. The precipitated salt mixture was treated with water to dissolve benzyl-t-butylaminohydrobromide. The crystals were filtered, washed with water and recrystallized by dissolving them in ethanol and then carrying out the recrystallization in absolute ether. The hydrobromide of (3,5-diacetoxy-6'-(benzyl-t-butylamino)-acetophenone has a melting point of 171°-173°C.

1,1 g av dette salt ble oppløst i varm absolutt etanol hvoretter 0. 1 g 10% palladium/trekull ble tilsatt. Oppløsningen ble så hydrogenert ved 50°C 1.1 g of this salt was dissolved in hot absolute ethanol after which 0.1 g of 10% palladium/charcoal was added. The solution was then hydrogenated at 50°C

og 5 atm. trykk over natten. Katalysatoren ble frafiltrert, og volumet av opp-løsningen redusert ved fordampning av oppløsningsmidlene. Med tilsetning av eter fikk man utfelt hydrobromidet av 1-(3', 5'-diacetoksyfenyl)-2-(t-butylamino)-etanol med 1 mol krystallvann. Smeltepunkt 108° - 111°C. De beskyt-tende acetylgrupper kan fjernes ved å koke 1 -(3 ', 5 '-.diacetoksyfenyl)-2-(t-butylamino)-etanolhydrobromid med 1% hydrobromsyre i 3 timer. Etter fordampning og tørking, kan produktet omkrystalliseres slik det er beskrevet under avsnitt 2 c). and 5 atm. pressure overnight. The catalyst was filtered off, and the volume of the solution reduced by evaporation of the solvents. With the addition of ether, the hydrobromide of 1-(3', 5'-diacetoxyphenyl)-2-(t-butylamino)-ethanol was precipitated with 1 mol of crystal water. Melting point 108° - 111°C. The protecting acetyl groups can be removed by boiling 1-(3',5'-diacetoxyphenyl)-2-(t-butylamino)-ethanol hydrobromide with 1% hydrobromic acid for 3 hours. After evaporation and drying, the product can be recrystallized as described under section 2 c).

På: analog måte oppnåes 1-(3', 5'-dihydroksyfenyl)-2-(t-butylamino) - etanol ved fjerning av acylgruppene i 1-(3', 5'-diisobutyryl-oksyfenyl)-2-(t-butylamino)-etanol, 1 - (3 ', 5 '-dipropionyloksyfenyl) -2-(t-butylamino)-etanol, og 1-(3',<5>'-di<p>ivalo<y>loks<y>fen<y>l)-2-(t-but<y>lamino)-etanol. Ovenfor benyttede ut-gangsmaterialer kan fremstilles på følgende måte: a) Fremstilling av 1 -(3 ', 5 '-diacetoksyfenyl)-2-(5 -butylamino)-etanol-hydrobromid. In an analogous way, 1-(3', 5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol is obtained by removing the acyl groups in 1-(3', 5'-diisobutyryl-oxyphenyl)-2-(t- butylamino)-ethanol, 1-(3',5'-dipropionyloxyphenyl)-2-(t-butylamino)-ethanol, and 1-(3',<5>'-di<p>ivalo<y>lox<y >phen<y>1)-2-(t-but<y>lamino)-ethanol. The starting materials used above can be prepared in the following way: a) Preparation of 1-(3', 5'-diacetoxyphenyl)-2-(5-butylamino)-ethanol hydrobromide.

1.0 g 3 , 5-diacetoksy-6j-(t-butylamino)-acetofenonhydrobromid ble oppløst i absolutt etanol og hydrogenert i en Parr-trykkreaktor ved 50°C og 5 atm. trykk i 17 timer i nærvær av 0. 1 g 10 % palladiumkull. 1.0 g of 3,5-diacetoxy-6j-(t-butylamino)-acetophenone hydrobromide was dissolved in absolute ethanol and hydrogenated in a Parr pressure reactor at 50°C and 5 atm. pressure for 17 hours in the presence of 0. 1 g of 10% palladium charcoal.

Katalysatoren ble filtrert og filtratets volum redusert ved avdampning. Hydrobromidet av 1-(3', 5'-diacetoksyfenyl)-2-(t-butylamino)-etanol ble br agt til krystallisering ved tilsetning av absolutt eter. Utbytte 0.5 g, smeltepunkt 108° -111°C. The catalyst was filtered and the volume of the filtrate reduced by evaporation. The hydrobromide of 1-(3', 5'-diacetoxyphenyl)-2-(t-butylamino)-ethanol was brought to crystallization by addition of absolute ether. Yield 0.5 g, melting point 108° -111°C.

På samme måte ble det således også fremstilt slike estere som 1-(3 ', 5 ' -diisobutyryloksyfenyl) -2-(t-butylamino) -etanolhydrobromid (smeltepunkt 168° - 170°C) og 1-(3 1, 5'-dipropionyloksyf enyl)-2-(t-butylamino)-etanolhydro-bromid (smeltepunkt 114° - 116°C). In the same way, such esters as 1-(3', 5'-diisobutyryloxyphenyl)-2-(t-butylamino)-ethanol hydrobromide (melting point 168° - 170°C) and 1-(3 1, 5' -dipropionyloxyphenyl)-2-(t-butylamino)-ethanol hydrobromide (melting point 114° - 116°C).

L L

b) Fremstilling av 3 , 5 -dihydroksy- CJ-( t -butylamino)-acetofenonhydro - bromid b) Preparation of 3,5-dihydroxy-CJ-(t-butylamino)-acetophenone hydrobromide

57.0 g 3 , 5-dibenzyloksy-cJ-(benzyl-t-butylamino)-acetofenon-hydro-bromid ble oppløst i 400 ml iseddik og hydrogenert ved atmosfæretrykk og romtemperatur i nærvær av 3. 0 g 10% palladiumkull. Når den beregnede mengde hydrogen var opptatt, ble hydrogeneringen avsluttet, Absolutt etanol ble tilsatt for å oppløse det dannede krystallinske produkt. Katalysatoren ble frafiltrert og filtratets volum redusert til krystalliseringen begynte. Utbytte 20.0 g 57.0 g of 3,5-dibenzyloxy-cJ-(benzyl-t-butylamino)-acetophenone hydrobromide was dissolved in 400 ml of glacial acetic acid and hydrogenated at atmospheric pressure and room temperature in the presence of 3.0 g of 10% palladium charcoal. When the calculated amount of hydrogen was taken up, the hydrogenation was terminated, Absolute ethanol was added to dissolve the crystalline product formed. The catalyst was filtered off and the volume of the filtrate reduced until crystallization began. Yield 20.0 g

c) Fremstilling av 3 , 5-diacetoksy-61-(t-butylamino)-acetofenonhydrobro-mid c) Preparation of 3,5-diacetoxy-61-(t-butylamino)-acetophenone hydrobromide

3.0 g 3 , 5-dihydroksy-^-(t-butylamino)-acetofenonhydrobromid ble kokt under tilbakeløp og omrøring med 2. 5 g eddiksyreanhydrid i 75 ml iseddik og under nitrogenatmosfære i 16 timer. Oppløsningsmidlet ble inndampet og resten oppløst i etanol. Ved tilsetning av absolutt eter ble det dannet et krystallinsk produkt bestående av 3, 5-diacetoksy-W-(t-butylamino)-acetofenonhydrobromid. Dette ble omkrystallisert fra metanol/eter. Utbytte 2.0 g, smeltepunkt 191°-193°C. 3.0 g of 3,5-dihydroxy-^-(t-butylamino)-acetophenone hydrobromide was refluxed and stirred with 2.5 g of acetic anhydride in 75 ml of glacial acetic acid and under a nitrogen atmosphere for 16 hours. The solvent was evaporated and the residue dissolved in ethanol. On addition of absolute ether, a crystalline product consisting of 3,5-diacetoxy-N-(t-butylamino)-acetophenone hydrobromide was formed. This was recrystallized from methanol/ether. Yield 2.0 g, melting point 191°-193°C.

d) Fremstilling av 3 ; 5 -dipivaloyloksy-<u-(benzyl-t-butylamino)-acetofe - nonhydroklorid d) Preparation of 3 ; 5-dipivaloyloxy-<u-(benzyl-t-butylamino)-acetophenone hydrochloride

16.0 g 3 ,5-dipivaloyloksy-4J-bromacetofenon oppløst i 200 ml tørr benzen ble forsynt med 22.0 g benzyl-t-butylamin. Reaksjonsblandingen ble kokt under tilbakeløp i 4 timer og fikk deretter stå ved romtemperatur i 15 timer. Benzenfasen ble inndampet til tørrhet og absolutt eter tilsatt. Benzyl-t-butyl-, aminhydrobromid utkrystalliserte seg og ble frafiltrert. 50 ml 10% hydrobromsyre ble tilsatt til filtratet under omrøring og dette ga et krystallinsk produkt bestående av 3 , 5 -dipivaloyloksy-^-(benzyl-t-butylamino)-acetofenonhydrobromid. Utbytte 11.0 g, smeltepunkt 162° - 167°C. 16.0 g of 3,5-dipivaloyloxy-4J-bromoacetophenone dissolved in 200 ml of dry benzene was supplied with 22.0 g of benzyl-t-butylamine. The reaction mixture was refluxed for 4 hours and then allowed to stand at room temperature for 15 hours. The benzene phase was evaporated to dryness and absolute ether added. Benzyl-t-butyl-, amine hydrobromide crystallized and was filtered off. 50 ml of 10% hydrobromic acid was added to the filtrate with stirring and this gave a crystalline product consisting of 3,5-dipivaloyloxy-^-(benzyl-t-butylamino)-acetophenone hydrobromide. Yield 11.0 g, melting point 162° - 167°C.

e) Fremstilling av 1-(3', 5 '-dipivaloyloksyfenyl) -2-(t-butylamino)-etanoJL-hydrobromid e) Preparation of 1-(3', 5'-dipivaloyloxyphenyl)-2-(t-butylamino)-ethane J hydrobromide

3.0 g 3,5 -dipivaloyloksy-<J-(benzyl-t-butylamino) -acetofenonhydrobro-mid ble oppløst i absolutt etanol og hydrogenert i en Parr-trykkreaktor i 20 timer ved 50°C og 5 atm. trykk i nærvær av 0.3 g 10% palladiumkull. Katalysatoren ble frafiltrert og filtratet inndampet til tørrhet. Resten ble krystallisert fra kloroform/eter/petroleumeter (kokepunkt 60° - 85°C). Utbytte 1.8 g, smeltepunkt 190° - 192°C. 3.0 g of 3,5-dipivaloyloxy-<J-(benzyl-t-butylamino)-acetophenone hydrobromide was dissolved in absolute ethanol and hydrogenated in a Parr pressure reactor for 20 hours at 50°C and 5 atm. pressure in the presence of 0.3 g of 10% palladium charcoal. The catalyst was filtered off and the filtrate evaporated to dryness. The residue was crystallized from chloroform/ether/petroleum ether (boiling point 60° - 85°C). Yield 1.8 g, melting point 190° - 192°C.

Æksempel 3 - Fremstilling av utgangsforbindelsen 1 -(3 1, 5 '-dibenzyloksyfenyl) - 2-( benzyl- t- butylamino) - etanol. Example 3 - Preparation of the starting compound 1-(3 1,5'-dibenzyloxyphenyl)-2-(benzyl-t-butylamino)-ethanol.

18.3 g 3 1, 5 '-dibenzyloksy-W-(benzyl-t-butylamino)-acetofenon i etanol ble tilsatt 2 g natriumborhydrid. Reaksjonsblandingen ble hensatt over natten, hvoretter metanol ble tilsatt og oppløsningen ble frafordampet oppløs-ningsmidlene. Residuet ble tilsatt vann og en 2 N natriumhydroksydoppløs-ning hvoretter vannfasen ble ekstrahert med eter. Eterfasen ble tørket med magnesiumsulfat, eteren ble så fordampet, og den gjenværende olje krystalliserte ved henstand. Smeltepunkt 78° - 79°C Det omkrystalliserte produkt kan omdannes til tilsvarende 2-butylaminoderivat ved å erstatte benzylgrup-pen med hydrogen på kjent måte. 18.3 g of 3 1,5'-dibenzyloxy-N-(benzyl-t-butylamino)-acetophenone in ethanol was added to 2 g of sodium borohydride. The reaction mixture was allowed to stand overnight, after which methanol was added and the solution was evaporated from the solvents. Water and a 2 N sodium hydroxide solution were added to the residue, after which the water phase was extracted with ether. The ether phase was dried with magnesium sulfate, the ether was then evaporated, and the remaining oil crystallized on standing. Melting point 78° - 79°C The recrystallized product can be converted into the corresponding 2-butylamino derivative by replacing the benzyl group with hydrogen in a known manner.

Eksempel 4 - Fremstilling av 1 -(3 ', 5 '-dihydroksyfenyl) -2-(t-butylamino) - Example 4 - Preparation of 1-(3',5'-dihydroxyphenyl)-2-(t-butylamino)-

etanolhydrobromid. ethanol hydrobromide.

2.4 g 3 , 5-dibenzyloksy-*J-(t-butylamino)-acetofenonhydrobromid i 200 ml iseddik ble hydrogenert i nærvær av 0.3 g 10% palladiumkull ved romtemperatur og normalt trykk. Etanol ble tilsatt for å oppløse utfelt reaksjons-produkt, katalysatoren ble frafiltrert og resten inndampet til tørrhet. 50 ml absolutt etanol ble tilsatt og oppløsningen hydrogenert i nærvær av 0.3 g 10% palladiumkull ved 35°C og 5 atm. trykk. Katalysatoren ble frafiltrert og resten inndampet til tørrhet. Omkrystallisering fra iseddik og kloroform: smeltepunkt 93°- 97°C (dekomponering). 2.4 g of 3,5-dibenzyloxy-*J-(t-butylamino)-acetophenone hydrobromide in 200 ml of glacial acetic acid was hydrogenated in the presence of 0.3 g of 10% palladium charcoal at room temperature and normal pressure. Ethanol was added to dissolve precipitated reaction product, the catalyst was filtered off and the residue evaporated to dryness. 50 ml of absolute ethanol was added and the solution hydrogenated in the presence of 0.3 g of 10% palladium charcoal at 35°C and 5 atm. Print. The catalyst was filtered off and the residue evaporated to dryness. Recrystallization from glacial acetic acid and chloroform: melting point 93°- 97°C (decomposition).

Eksempel 5 - Fremstilling av (-)-1-(3', 5'-dihydroksyfenyl)-2-tert.butylamino- etanol- hydrobromid. Example 5 - Preparation of (-)-1-(3', 5'-dihydroxyphenyl)-2-tert-butylamino-ethanol hydrobromide.

Først fremstilles utgangsmaterialet ved spaltning av 1-(3 ', 5 '-dibenzyloksyfenyl)-2-(benzyl-tert.butylamino)-etanol i optisk antipoder. First, the starting material is prepared by cleavage of 1-(3', 5'-dibenzyloxyphenyl)-2-(benzyl-tert.butylamino)-ethanol in optical antipodes.

Således ble 25.0 g 1-(3', 5 1-dibenzyloksyfenyl) -2-(benzyl-t-butylamino)-etanol (Racematformen av basen) oppløst i 3 75 ml metanol ved oppvarm-ing hvoretter 19.0 g (-)dibenzoyl-vinsyre i 125 ml metanol ble tilsatt. Blandingen ble kokt under tilbakeløp i 30 minutter. Etter inndamping ble en olje oppnådd. Denne ble oppløst i kokende isopropanol og vann ble tilsatt til denne blanding til en uklarhet viste seg, hvoretter noen få ml isopropanol ble tilsatt for å klare oppløsningen. Oppløsningen fikk stå natten over for å krystalli-seres og 37.0 g av et hvitt krystallinsk produkt ble isolert. Ytterligere 7. Og ble oppnådd fra filtratet etter redusering av dets volum. De to porsjonene ble blandet og oppløst i 1100 ml absolutt etanol, filtrert og fikk krystallisere. Dette produkt ble omkrystallisert fra absolutt etanol til dreiingen forble kon-stant (6 ganger) [» -34. 2°C (1% i absolutt metanol), utbytte 4.5 g. Thus, 25.0 g of 1-(3', 5 1-dibenzyloxyphenyl)-2-(benzyl-t-butylamino)-ethanol (the racemate form of the base) was dissolved in 3 75 ml of methanol by heating, after which 19.0 g of (-)dibenzoyl- tartaric acid in 125 ml of methanol was added. The mixture was refluxed for 30 minutes. After evaporation, an oil was obtained. This was dissolved in boiling isopropanol and water was added to this mixture until a cloud appeared, after which a few ml of isopropanol were added to clear the solution. The solution was allowed to stand overnight to crystallize and 37.0 g of a white crystalline product was isolated. Additional 7. And was obtained from the filtrate after reducing its volume. The two portions were mixed and dissolved in 1100 ml of absolute ethanol, filtered and allowed to crystallize. This product was recrystallized from absolute ethanol until the rotation remained constant (6 times) [» -34. 2°C (1% in absolute methanol), yield 4.5 g.

4.0 g av saltet som oppnås ovenfor, ble suspendert i vann, hvoretter føTst eter ble tilsatt og deretter vannholdig ammoniakk. Basen ble deretter 4.0 g of the salt obtained above was suspended in water, after which ether was added and then aqueous ammonia. The base then became

ekstrahert med to porsjoner eter. Fortynnet hydrobromsyre ble tilsatt til eterfasen som deretter ble omrørt i 1.5 time. Dette ga et hvitt krystallinsk produkt, som ble frafiltrert og vasket med vann og tørr eter. Utbytte 2. 8 g, f *7D°C +33. 3° (1% i absolutt metanol). extracted with two portions of ether. Dilute hydrobromic acid was added to the ether phase which was then stirred for 1.5 hours. This gave a white crystalline product, which was filtered off and washed with water and dry ether. Yield 2. 8 g, f *7D°C +33. 3° (1% in absolute methanol).

Denne forbindelse ble oppløst i 75 ml absolutt etanol, hvoretter 0. 15g 10% palladiumkull ble tilsatt og blandingen ble deretter hydrogenert ved romtemperatur i 4 timer ved 5 atm. trykk. Katalysatoren ble frafiltrert og resten inndampet til tørrhet. Et lite volum metanol ble tilsatt for å oppløse produktet og deretter eter til uklarhet oppsto. Den krystallinske felling ble fraskilt etter at blandingen hadde fått stå i avtrekk og tørket i tørkepistol (drying pistol) i 7 timer (over kokende toluen). Utbytte 1.2 g. Br (beregnet)- 26. 1%; Br (funnet) - 25.8% /"«7D°* -34.6° (l% i absolutt metanol). This compound was dissolved in 75 ml of absolute ethanol, after which 0.15 g of 10% palladium charcoal was added and the mixture was then hydrogenated at room temperature for 4 hours at 5 atm. Print. The catalyst was filtered off and the residue evaporated to dryness. A small volume of methanol was added to dissolve the product and then ether until cloudiness occurred. The crystalline precipitate was separated after the mixture had been allowed to stand in a fume hood and dried in a drying gun (drying gun) for 7 hours (over boiling toluene). Yield 1.2 g. Br (calculated)- 26. 1%; Br (found) - 25.8% /"«7D°* -34.6° (1% in absolute methanol).

Eksempel 6 - Fremstilling av (+).-!-(3 ', 5 '-dihydroksyfenyl) -2-(t-butylamino) - Example 6 - Preparation of (+).-!-(3', 5'-dihydroxyphenyl)-2-(t-butylamino)-

etanolhydrobromid ethanol hydrobromide

23.5 g av basen 1-(3', 5'-dibenzyloksyfenyl)-2-(benzyl-t-butylamino) - 23.5 g of the base 1-(3', 5'-dibenzyloxyphenyl)-2-(benzyl-t-butylamino) -

etanol oppnådd fra de samlede fraskilte oppløsningene fra fremstillingen av (-)-1-(3', 5 '-dibenzyloksyfenyl)-2-(benzyl-t-butylamino)-etanol, ble oppløst i 250 ml metanol og kokt under tilbakeløp sammen med 18. 2 g (+)-dibenzoyl-vinsyre opp-løst i 250 ml metanol og kokt under tilbakeløp i 60 minutter. Produktet ble be-arbeidet på samme måte som beskrevet ovenfor og omkrystallisert to ganger fra absolutt etanol. /"«7D°« +34.3° (1% i absolutt metanol). Utbytte 10.5 g. ethanol obtained from the combined separated solutions from the preparation of (-)-1-(3', 5'-dibenzyloxyphenyl)-2-(benzyl-t-butylamino)-ethanol was dissolved in 250 ml of methanol and refluxed together with 18. 2 g of (+)-dibenzoyl-tartaric acid dissolved in 250 ml of methanol and boiled under reflux for 60 minutes. The product was processed in the same way as described above and recrystallized twice from absolute ethanol. /"«7D°« +34.3° (1% in absolute methanol). Yield 10.5 g.

Hydrobromidet ble fremstilt av 9. 5 g av dette salt på samme måte som beskrevet ovenfor. Utbytte 6.2g, /*7D°- -33.0° (l% i absolutt metanol). Hydrogeneringen av 5.5 g av dette produkt ble utført som beskrevet ovenfor. Reaksjonsproduktet krystalliserte seg fra etanol/eter. Utbytte 2.5 g, [*-]^"+ 34.2° (1% i absolutt metanol). Br" (beregnet) « 26.1%, Br" (funnet) =• 25.8%, smeltepunkt 241° - 243°C. The hydrobromide was prepared from 9.5 g of this salt in the same manner as described above. Yield 6.2g, /*7D°- -33.0° (1% in absolute methanol). The hydrogenation of 5.5 g of this product was carried out as described above. The reaction product crystallized from ethanol/ether. Yield 2.5 g, [*-]^"+ 34.2° (1% in absolute methanol). Br" (calculated) « 26.1%, Br" (found) =• 25.8%, melting point 241° - 243°C.

Farmakologiske undersøkelser Pharmacological investigations

A. Bronkospasmolytisk effekt. A. Bronchospasmolytic effect.

Den bronkospasmolytiske effekt for 1 -(3', 5 '-dihydroksyfenyl)-2-(t-butylamino)-etanol ble sammenlignet med effekten til de kjente forbindelsene adrenalin og l-(3' , 5 '-dihydroksyfenyl)-2 - (i-propylamino)-etanol på spiralskåret trakea fra marsvin ifølge den metode som opprinnelig er beskrevet av Castillo og Beer (j. Pharmacol. Exptl. Therap. 90 (1947), 104) og senere modifisert av Constantine (J. Pharm. Pharmcol. 17 (1965), 384). Ved denne undersøkelse ble det funnet at forbindelsen fremstilt ifølge oppfinnelsen var omkring 1.5 ganger så aktiv som isopropylforbindelsen og omtrent halvparten så virksom som adrenalin. The bronchospasmolytic effect of 1-(3',5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol was compared with the effect of the known compounds adrenaline and l-(3',5'-dihydroxyphenyl)-2-( i-propylamino)-ethanol on helically cut guinea-pig trachea according to the method originally described by Castillo and Beer (j. Pharmacol. Exptl. Therap. 90 (1947), 104) and later modified by Constantine (J. Pharm. Pharmcol. 17 (1965), 384). In this investigation, it was found that the compound produced according to the invention was about 1.5 times as active as the isopropyl compound and about half as effective as adrenaline.

Ved et in vivo forsøk ifølge Konzett og Rbssler (Arch. Exp. Path. Phar-mak. 195 (1940), 71) var den bronkospasmolytiske effekt etter i. v. administrasjon også 1.5 ganger effekten for isopropylforbindelsen. In an in vivo experiment according to Konzett and Rbssler (Arch. Exp. Path. Phar-mak. 195 (1940), 71), the bronchospasmolytic effect after i. v. administration was also 1.5 times the effect for the isopropyl compound.

Varigheten av effekten ble funnet å være lengre enn for det kjente isopropylderivatet (fig. 1:DTE * 1 - (3 ', 5 1 -dihydroksyfenyl)-2-(t-butylamino) - etanol; DIE = 1-(3 1, 5'-dihydroksyfenyl)-2-(i-propylamino)-etanol. The duration of the effect was found to be longer than that of the known isopropyl derivative (Fig. 1: DTE * 1 - (3 ', 5 1 -dihydroxyphenyl)-2-(t-butylamino) - ethanol; DIE = 1-(3 1, 5'-dihydroxyphenyl)-2-(i-propylamino)-ethanol.

B. Effekt på hjertet B. Effect on the heart

Forholdet mellom den hjertestimulerende effekt og bronkodilator-effekten ble studert in vitro på aurikel-trakea-preparater fra marsvin. For å sammenligne effekten på hjerte og effekten på bronkialmusklene under i-dentiske eksperimentelle forhold, ble både spontant slående aurikel og spiralskåret trakea plasert i samme bad i Krebs oppløsning. Begge preparatene ble tatt fra6amme dyr. Forsøksforbindelsene ble langsomt infusert i bad - oppløsningen. På denne måten ble konsentrasjonen av forbindelsen langsomt hevet og det var lett å observere på hvilken muskel forbindelsen var mest ef-fektiv. Adrenalin ble benyttet som referanse. Denne forbindelse forårsaker bronkodilatering og hjertemuskelstimulering i samme konsentrasjonsområde. Infusjonen ble foretatt i 10 minutter. Etter vasking og gjenvinning, ble for-søksoppløsningen infusert på samme måte som beskrevet for adrenalin, og effekten på de to preparatene for denne forbindelse kunne lett sammenlignes med effekten for adrenalin. The relationship between the cardiac stimulating effect and the bronchodilator effect was studied in vitro on auricle-trachea preparations from guinea pigs. To compare the effect on the heart and the effect on the bronchial muscles under identical experimental conditions, both the spontaneously beating auricle and spirally cut trachea were placed in the same bath in Krebs' solution. Both preparations were taken from lactating animals. The test compounds were slowly infused into the bath solution. In this way, the concentration of the compound was slowly raised and it was easy to observe on which muscle the compound was most effective. Adrenaline was used as a reference. This compound causes bronchodilation and cardiac muscle stimulation in the same concentration range. The infusion was carried out for 10 minutes. After washing and recovery, the test solution was infused in the same manner as described for adrenaline, and the effect on the two preparations for this compound could easily be compared with the effect for adrenaline.

Som det fremgår av fig. 2 ble det funnet at 1-(3', 5 '-dihydroksyfenyl) - 2-(t-butylamino)-etanol (DTE) forårsaker bronkodilatering uten hj erte stimuler - ing. Som sammenligning er effekten av noradrenalin (NA), isoprenalin (IPR) og 1-(3', 5'-dihydroksyfenyl)-2-(i-propylamino)-etanol (DIE) på dette preparat, gitt i fig. 3 og 4. Noradrenalin som er en dårlig bronkodilator, stimulerer hjertemuskelen uten å angripe bronkialmusklene. Som det fremgår fra fig. 4 er både isoprenalin og DIE sterke hjertestimulatorer i forhold til sin bronkodilator effekt. As can be seen from fig. 2, it was found that 1-(3', 5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol (DTE) causes bronchodilation without cardiac stimulation. As a comparison, the effect of norepinephrine (NA), isoprenaline (IPR) and 1-(3', 5'-dihydroxyphenyl)-2-(i-propylamino)-ethanol (DIE) on this preparation is given in fig. 3 and 4. Norepinephrine, which is a poor bronchodilator, stimulates the heart muscle without attacking the bronchial muscles. As can be seen from fig. 4, both isoprenaline and DIE are strong cardiac stimulators in relation to their bronchodilator effect.

Den hjertestimulerende virkning ble også studert på isolert kaninhjerte (Langendorff-preparat). Som det fremgår fra fig. 5 er den kardioakselererende effekt for forbindelsen fremstilt ifølge oppfinnelsen svak og bare omkring l/50 av effekten for adrenalin. Effekten for DIE på dette preparat er vist på fig. 6. Den kardioakselererende effekt for dette middel var i dette forsøk omkring l/4 av den til adrenalin. The cardiac stimulating effect was also studied on isolated rabbit heart (Langendorff preparation). As can be seen from fig. 5, the cardioaccelerating effect for the compound produced according to the invention is weak and only about 1/50 of the effect for adrenaline. The effect of DIE on this preparation is shown in fig. 6. The cardioaccelerating effect of this agent was in this experiment about 1/4 of that of adrenaline.

Toksisitetsundersøkelse Toxicity study

Toksisiteten for 1 -(3 ', 5 '-dihydroksyfenyl) - 2-(t-butylamino) - etanol The toxicity of 1-(3',5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol

-(DTE) i mus etter i. v. , s.c. og oral administrasjon er gitt i tabell I. For sammenligning er tilsvarende LDj-q-verdier for 1-(3', 5 '-dihydroksyfenyl)-2-(i-prpylamino)-etanol (DIE), gitt. -(DTE) in mice after i.v., s.c. and oral administration are given in Table I. For comparison, corresponding LDj-q values for 1-(3', 5'-dihydroxyphenyl)-2-(i-propylamino)-ethanol (DIE) are given.

Claims (1)

Fremgangsmåte til fremstilling av en bronkospasmolytisk virksom forbindelse med formelen: Method for producing a bronchospasmolytically active compound with the formula: og fysiologisk akseptable syreaddisjonssalter derav,karakterisert vedA. at en dikarbonylforbindelse med formel III omsettes med tert. -butylamin med formel IV under samtidig reduksjon ifølge følgende reaksjonsskjema: and physiologically acceptable acid addition salts thereof, characterized byA. that a dicarbonyl compound of formula III is reacted with tert. -butylamine with formula IV during simultaneous reduction according to the following reaction scheme: hvoretter R , om nødvendig, erstattes med hydrogen, eller B. at et epoksyd av formel VI omsettes med en forbindelse av formel VII ifølge følgende reaksjonsskjema: after which R , if necessary, is replaced by hydrogen, or B. that an epoxide of formula VI is reacted with a compound of formula VII according to the following reaction scheme: hvoretter R 3 og R 4, om nødvendig, erstattes med hydrogen, eller C. at en forbindelse med formel IX reduseres ifølge følgende reaksjonsskjema: 3 4 hvoretter R og R , om nødvendig, erstattes med hydrogen, i hvilke formler R 3er hydrogen eller en alkyl- eller alkanoylgruppe med høyst 5 karbonatomer eller en mono- eller bicyklisk aralkylgruppe med høyst 11 karbonatomer, slik som .benzyl eller naftylmetyl, og R 4er hydrogen eller en mono-eller bicyklisk aralkylgruppe med høyst 11 karbonatomer, hvoretter den erholdte forbindelse om ønsket omdannes til fysiologisk tålbare syreaddisjonssalter, og/eller oppdeles i sine optisk aktive former enten før eller etter avspaltningen av beskyttelsesgruppene R 3 og// eller R<4>.after which R 3 and R 4 are, if necessary, replaced by hydrogen, or C. that a compound of formula IX is reduced according to the following reaction scheme: 3 4 after which R and R , if necessary, are replaced by hydrogen, in which formulas R 3 is hydrogen or an alkyl or alkanoyl group of up to 5 carbon atoms or a mono- or bicyclic aralkyl group of up to 11 carbon atoms, such as .benzyl or naphthylmethyl, and R 4 is hydrogen or a mono- or bicyclic aralkyl group of up to 11 carbon atoms , after which the obtained compound is, if desired, converted into physiologically tolerable acid addition salts, and/or split into its optically active forms either before or after the cleavage of the protective groups R 3 and// or R<4>.
NO170180A 1966-10-19 1967-10-18 NO120686B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO128170A NO124723B (en) 1967-10-18 1970-04-07
NO302670A NO132866C (en) 1966-10-19 1970-08-05

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE14182/66A SE335359B (en) 1966-10-19 1966-10-19

Publications (1)

Publication Number Publication Date
NO120686B true NO120686B (en) 1970-11-23

Family

ID=20298669

Family Applications (1)

Application Number Title Priority Date Filing Date
NO170180A NO120686B (en) 1966-10-19 1967-10-18

Country Status (13)

Country Link
AT (4) AT288356B (en)
BE (1) BE704932A (en)
CH (1) CH510625A (en)
DE (2) DE1643296C3 (en)
DK (2) DK128491B (en)
ES (5) ES346131A1 (en)
FI (1) FI50786C (en)
FR (1) FR8011M (en)
GB (1) GB1199630A (en)
IT (1) IT8048168A0 (en)
NL (2) NL151693B (en)
NO (1) NO120686B (en)
SE (1) SE335359B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419364A (en) 1980-07-09 1983-12-06 Aktiebolaget Draco Bronchospasmolytic carbamate derivatives

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138581A (en) 1969-04-01 1979-02-06 Sterling Drugs Inc. 3(Hydroxy or hydroxymethyl)-4(hydroxy)-α-(aminomethyl)benzyl alcohols
EP0046144B1 (en) * 1980-07-09 1984-04-11 Aktiebolaget Draco Therapeutically active derivatives of phenylethanol amines
US4853381A (en) * 1984-04-17 1989-08-01 Glaxo Group Limited Ethanolamine compounds
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
EP0213108A3 (en) * 1985-06-26 1987-07-15 Kurt Dr. Burghart Pharmaceutical preparation containing an antihypotonic as the active agent
WO2013081565A1 (en) 2011-11-21 2013-06-06 Mahmut Bilgic Pharmaceutical compositions comprising roflumilast and terbutaline
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
WO2018182546A1 (en) 2017-03-27 2018-10-04 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Stabilized pharmaceutical syrup composition comprising terbutaline sulphate and ambroxol hydrochloride
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN110057932B (en) * 2019-04-22 2022-03-15 上海旭东海普药业有限公司 Method for analyzing terbutaline sulfate related substances by high performance liquid chromatography
CN111440078A (en) * 2020-04-26 2020-07-24 梯尔希(南京)药物研发有限公司 Preparation method of terbutaline derivative
CN113264839B (en) * 2021-04-27 2022-08-30 苏州弘森药业股份有限公司 Method for preparing levo-terbutaline by using chiral prosthetic group
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419364A (en) 1980-07-09 1983-12-06 Aktiebolaget Draco Bronchospasmolytic carbamate derivatives

Also Published As

Publication number Publication date
AT287679B (en) 1971-02-10
ES361433A1 (en) 1970-11-01
SE335359B (en) 1971-05-24
FI50786B (en) 1976-03-31
AT286964B (en) 1971-01-11
ES361431A1 (en) 1970-11-01
DE1793759A1 (en) 1973-08-16
DE1643296A1 (en) 1971-09-30
NL7513854A (en) 1976-03-31
GB1199630A (en) 1970-07-22
ES361429A1 (en) 1970-11-01
CH510625A (en) 1971-07-31
DK128491B (en) 1974-05-13
ES361432A1 (en) 1970-11-01
NL151693B (en) 1976-12-15
DE1793759C3 (en) 1979-01-11
FI50786C (en) 1976-07-12
DE1643296C3 (en) 1974-06-12
NL6714191A (en) 1968-04-22
DK468876A (en) 1976-10-18
AT287678B (en) 1971-02-10
AT288356B (en) 1971-03-10
DE1793759B2 (en) 1978-05-11
IT8048168A0 (en) 1980-03-14
DE1643296B2 (en) 1973-10-25
BE704932A (en) 1968-02-15
ES346131A1 (en) 1969-05-16
FR8011M (en) 1970-07-27

Similar Documents

Publication Publication Date Title
NO120686B (en)
KR880002310B1 (en) Process for producing phenethanol amines
NO135140B (en)
NO166164B (en) EQUIPMENT FOR AA ESTABLISH ELECTRICAL CONNECTION WITH A SINGLE SKIN ELECTRODE.
EP0147475A1 (en) Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
JPS6341910B2 (en)
US4855422A (en) Process for the preparation of azoniaspironortropanol esters
US4614806A (en) Process for the asymmetric synthesis of chiral indoline-2-carboxylic acids
NO140378B (en) PROCEDURE FOR PREPARING 1- (3,5-DIHYDROXYPHENYL) -1-HYDROXY-2- (1-METHYL-2- (4-HYDROXYPHENYL) -ETHYL) -AMINOETANE
US4822895A (en) 3-aminoazetidine, its salts and intermediates of synthesis
US3065265A (en) Amino acid hydrazides
US4283410A (en) 3-Amino or amido-2-(1H-indol-3-yl) propanoic acid derivatives
JPS61500615A (en) chemical synthesis
BOSE et al. Some Derivatives of Glycineamidine1
US3775479A (en) Amine compounds
NO132866B (en)
US4304930A (en) Process for the preparation of 2-(3-phenoxy-phenyl)-propionic acid
GB2023590A (en) 3-amino-2-(5-fluoro and 5- methoxy-1H-indol-3-yl) Propanoic Acid Derivatives and Their Preparation and Use
NO126437B (en)
EP0489548B1 (en) A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof
Melone et al. Tropine dl-α-methyltropate (methylatropine) and its optical antipodes
US2970159A (en) Hydrazine derivatives
US3947584A (en) Novel indolyl alkyl amines, method of producing same, and their use as anorectic agents
US4283336A (en) Process for the preparation of 3-amino-2-(5-fluoro and 5-methoxy-1H-indol-3-yl)propanoic acid derivatives
NO781896L (en) 4-PHENYL-8-AMINO-TETRAHYDROISOCHINOLINS, PHARMACEUTICAL PREPARATIONS CONTAINING THESE, PROCEDURES FOR THE PREPARATION OF THESE PREPARATIONS AND THEIR USE AS ANTI-PREPARATIONS